FULVESTRANT EG LABO 250 mg, solution for injection in a pre-filled syringe syringe, 5 ml
Active ingredients: Fulvestrant
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 5 mlintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- FULVESTRANT EG LABO 250 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- intramusculaire
- Presentation description
- 1 seringue préremplie en verre de 5 mL avec aiguille
- Marketing authorisation holder
- EG LABO - LABORATOIRES EUROGENERICS
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 20 Jul 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65606558CIP73030195CIP133400930301951Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FULVESTRANTsolution | 250 mg · une seringue préremplie de 5 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.